GU Cancers 2025 | The role of immunotherapy after radiation in bladder cancer
Robert Huddart, PhD, FRCR, MBBS, MRCP, The Institute of Cancer Research, London, UK, discusses the combination of radiation with immunotherapy in locally advanced bladder cancer. While adjuvant treatment has shown benefits post-cystectomy, data following radiation remains limited, with ongoing trials exploring its potential. Immunotherapy, particularly pembrolizumab, has demonstrated efficacy in preventing non-muscle invasive cancer progression. Prof. Huddart also remarks on the accessibility of immunotherapy in the UK. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
